Skip to main content
Top
Published in: Supportive Care in Cancer 4/2024

Open Access 01-04-2024 | Melanoma | Research

What patients with advanced cancer experience as helpful in navigating their life with a long-term response: a qualitative study

Authors: Laura C. Zwanenburg, Marije L. van der Lee, José J. Koldenhof, Karijn P. M. Suijkerbuijk, Melanie P. J. Schellekens

Published in: Supportive Care in Cancer | Issue 4/2024

Login to get access

Abstract

Purpose

Despite improved survival for people with advanced cancer due to new medical treatments, a growing group of long-term responders (LTRs) has to learn to live with uncertainties that affect several life domains. At the core of their experience, they neither feel like a patient nor feel healthy. Despite growing awareness of LTRs’ experiences, learning more about how they cope with their long-term response can provide insight into how to best support them. Our study aimed to gain a deeper understanding what LTRs experience as helpful in navigating life with a long-term response.

Methods

We conducted an exploratory qualitative study using thematic data analysis. Semi-structured in-depth interviews were conducted with 17 participants with advanced melanoma or lung cancer with confirmed response or long-term stable disease while on immuno- or targeted therapy.

Results

LTRs reported several strategies to navigate life with a long-term response, for example, by involving the social environment, seeing uncertainty as an opportunity, and being present in the moment. This helped them to reclaim a sense of control, alter their perspective, and reshape their lives according to their values.

Conclusion

Using different coping strategies enables LTRs to acknowledge both their sick and healthy side. Striking a healthy balance between being oriented on feeling sick or feeling healthy can help LTRs and their close others to navigate life with a long-term response. Healthcare professionals can provide support by recognizing whether LTRs are oriented at feeling sick or healthy, and by actively involving close others during medical appointments.
Literature
1.
go back to reference Zwanenburg LC, Suijkerbuijk KPM, van Dongen SI, Koldenhof JJ, van Roozendaal AS, van der Lee ML et al (2022) Living in the twilight zone: a qualitative study on the experiences of patients with advanced cancer obtaining long-term response to immunotherapy or targeted therapy. J Cancer Surviv 1–11 Zwanenburg LC, Suijkerbuijk KPM, van Dongen SI, Koldenhof JJ, van Roozendaal AS, van der Lee ML et al (2022) Living in the twilight zone: a qualitative study on the experiences of patients with advanced cancer obtaining long-term response to immunotherapy or targeted therapy. J Cancer Surviv 1–11
2.
go back to reference Kolsteren EEM, Deuning-Smit E, Chu AK, van der Hoeven YCW, Prins JB, van der Graaf WTA et al (2022) Psychosocial aspects of living long term with advanced cancer and ongoing systemic treatment: a scoping review. Cancers (Basel) 14:3889CrossRefPubMed Kolsteren EEM, Deuning-Smit E, Chu AK, van der Hoeven YCW, Prins JB, van der Graaf WTA et al (2022) Psychosocial aspects of living long term with advanced cancer and ongoing systemic treatment: a scoping review. Cancers (Basel) 14:3889CrossRefPubMed
3.
go back to reference Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn M-J et al (2019) Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 37(28):2518–527CrossRefPubMedPubMedCentral Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn M-J et al (2019) Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 37(28):2518–527CrossRefPubMedPubMedCentral
4.
go back to reference Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD et al (2022) Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 40:127–137CrossRefPubMed Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD et al (2022) Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 40:127–137CrossRefPubMed
5.
go back to reference Dunn J, Watson M, Watson JF, Hyde MK (2017) Systematic review of psychosocial outcomes for patients with advanced melanoma. Psychooncology. John Wiley and Sons Ltd, pp 1722–31 Dunn J, Watson M, Watson JF, Hyde MK (2017) Systematic review of psychosocial outcomes for patients with advanced melanoma. Psychooncology. John Wiley and Sons Ltd, pp 1722–31
6.
go back to reference McFarland DC (2019) New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy. Gen Hosp Psychiatry 60:148–155CrossRefPubMedPubMedCentral McFarland DC (2019) New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy. Gen Hosp Psychiatry 60:148–155CrossRefPubMedPubMedCentral
7.
go back to reference Levy D, Dhillon HM, Lomax A, Marthick M, McNeil C, Kao S et al (2019) Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. Support Care Cancer 27:1845–1852CrossRefPubMed Levy D, Dhillon HM, Lomax A, Marthick M, McNeil C, Kao S et al (2019) Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. Support Care Cancer 27:1845–1852CrossRefPubMed
8.
go back to reference Lai-Kwon J, Khoo C, Lo S, Milne D, Mohamed M, Raleigh J et al (2019) The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. J Cancer Surviv 13:503–511CrossRefPubMed Lai-Kwon J, Khoo C, Lo S, Milne D, Mohamed M, Raleigh J et al (2019) The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. J Cancer Surviv 13:503–511CrossRefPubMed
9.
go back to reference Shilling V, Starkings R, Jenkins V, Fallowfield L (2017) The pervasive nature of uncertainty—a qualitative study of patients with advanced cancer and their informal caregivers. J Cancer Surviv 11:590–603CrossRefPubMedPubMedCentral Shilling V, Starkings R, Jenkins V, Fallowfield L (2017) The pervasive nature of uncertainty—a qualitative study of patients with advanced cancer and their informal caregivers. J Cancer Surviv 11:590–603CrossRefPubMedPubMedCentral
10.
go back to reference Petrillo LA, Traeger LN, Sommer RK, Zhou AZ, Temel JS, Greer JA (2021) Experience and supportive care needs of metastatic lung cancer survivors living with uncertainty: a brief qualitative report. J Cancer Surviv 15:386–391CrossRefPubMed Petrillo LA, Traeger LN, Sommer RK, Zhou AZ, Temel JS, Greer JA (2021) Experience and supportive care needs of metastatic lung cancer survivors living with uncertainty: a brief qualitative report. J Cancer Surviv 15:386–391CrossRefPubMed
11.
go back to reference Kamminga NCW, van der Veldt AAM, Joosen MCW, de Joode K, Joosse A, Grünhagen DJ et al (2022) Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma. Br J Dermatol 187(3):381–391CrossRefPubMedPubMedCentral Kamminga NCW, van der Veldt AAM, Joosen MCW, de Joode K, Joosse A, Grünhagen DJ et al (2022) Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma. Br J Dermatol 187(3):381–391CrossRefPubMedPubMedCentral
12.
go back to reference Ala-Leppilampi K, Baker NA, McKillop C, Butler MO, Siu LL, Spreafico A et al (2020) Cancer patients’ experiences with immune checkpoint modulators: a qualitative study. Cancer Med 9:3015–3022CrossRefPubMedPubMedCentral Ala-Leppilampi K, Baker NA, McKillop C, Butler MO, Siu LL, Spreafico A et al (2020) Cancer patients’ experiences with immune checkpoint modulators: a qualitative study. Cancer Med 9:3015–3022CrossRefPubMedPubMedCentral
13.
go back to reference Langmuir T, Chu A, Sehabi G, Giguère L, Lamarche J, Boudjatat W et al (2023) A new landscape in illness uncertainty: a systematic review and thematic synthesis of the experience of uncertainty in patients with advanced cancer receiving immunotherapy or targeted therapy. Psycho-oncology 32(3):356–367CrossRefPubMed Langmuir T, Chu A, Sehabi G, Giguère L, Lamarche J, Boudjatat W et al (2023) A new landscape in illness uncertainty: a systematic review and thematic synthesis of the experience of uncertainty in patients with advanced cancer receiving immunotherapy or targeted therapy. Psycho-oncology 32(3):356–367CrossRefPubMed
14.
go back to reference Smith AL, Hart NH, Jefford M, Chan RJ (2022) Survivorship research for people with metastatic or advanced cancer: a time for action. Asia Pac J Oncol Nurs 9:185–186CrossRefPubMedPubMedCentral Smith AL, Hart NH, Jefford M, Chan RJ (2022) Survivorship research for people with metastatic or advanced cancer: a time for action. Asia Pac J Oncol Nurs 9:185–186CrossRefPubMedPubMedCentral
15.
go back to reference Mollica MA, Smith AW, Tonorezos E, Castro K, Filipski KK, Guida J et al (2022) Survivorship for individuals living with advanced and metastatic cancers: National Cancer Institute Meeting Report. JNCI: J Natl Cancer Inst 114:489–95CrossRefPubMed Mollica MA, Smith AW, Tonorezos E, Castro K, Filipski KK, Guida J et al (2022) Survivorship for individuals living with advanced and metastatic cancers: National Cancer Institute Meeting Report. JNCI: J Natl Cancer Inst 114:489–95CrossRefPubMed
16.
go back to reference Braun V, Clarke V. Thematic analysis: a practical guide. Maher A, editor. London: SAGE Publications Ltd; 2022 Braun V, Clarke V. Thematic analysis: a practical guide. Maher A, editor. London: SAGE Publications Ltd; 2022
17.
go back to reference Burgers VWG, van den Bent MJ, Rietjens JAC, Roos DC, Dickhout A, Franssen SA et al (2022) “Double awareness”—adolescents and young adults coping with an uncertain or poor cancer prognosis: a qualitative study. Front Psychol 13:1–12CrossRef Burgers VWG, van den Bent MJ, Rietjens JAC, Roos DC, Dickhout A, Franssen SA et al (2022) “Double awareness”—adolescents and young adults coping with an uncertain or poor cancer prognosis: a qualitative study. Front Psychol 13:1–12CrossRef
18.
go back to reference García-Rueda N, Carvajal Valcárcel A, Saracíbar-Razquin M, Arantzamendi SM (2016) The experience of living with advanced-stage cancer: a thematic synthesis of the literature. Eur J Cancer Care (Engl) 25:551–569CrossRefPubMed García-Rueda N, Carvajal Valcárcel A, Saracíbar-Razquin M, Arantzamendi SM (2016) The experience of living with advanced-stage cancer: a thematic synthesis of the literature. Eur J Cancer Care (Engl) 25:551–569CrossRefPubMed
19.
go back to reference Arantzamendi M, García-Rueda N, Carvajal A, Robinson CA (2020) People with advanced cancer: the process of living well with awareness of dying. Qual Health Res 30:1143–1155CrossRefPubMed Arantzamendi M, García-Rueda N, Carvajal A, Robinson CA (2020) People with advanced cancer: the process of living well with awareness of dying. Qual Health Res 30:1143–1155CrossRefPubMed
21.
go back to reference Kvåle K, Synnes O (2018) Living with life-prolonging chemotherapy-control and meaning-making in the tension between life and death. Eur J Cancer Care (Engl) 27:e12770CrossRef Kvåle K, Synnes O (2018) Living with life-prolonging chemotherapy-control and meaning-making in the tension between life and death. Eur J Cancer Care (Engl) 27:e12770CrossRef
22.
go back to reference Masten AS, Lucke CM, Nelson KM, Stallworthy IC (2021) Resilience in development and psychopathology: multisystem perspectives. Annu Rev Clin Psychol 17:521–549CrossRefPubMed Masten AS, Lucke CM, Nelson KM, Stallworthy IC (2021) Resilience in development and psychopathology: multisystem perspectives. Annu Rev Clin Psychol 17:521–549CrossRefPubMed
23.
go back to reference Lai-Kwon J, Heynemann S, Flore J, Dhillon H, Duffy M, Burke J et al (2021) Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy. J Cancer Surviv 15:392–397CrossRefPubMed Lai-Kwon J, Heynemann S, Flore J, Dhillon H, Duffy M, Burke J et al (2021) Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy. J Cancer Surviv 15:392–397CrossRefPubMed
24.
go back to reference Stroebe M, Schut H (2010) The dual process model of coping with bereavement: a decade on. OMEGA - J Death Dying 61:273–289CrossRef Stroebe M, Schut H (2010) The dual process model of coping with bereavement: a decade on. OMEGA - J Death Dying 61:273–289CrossRef
25.
26.
go back to reference Coyne JC, Smith DA (1991) Couples coping with a myocardial infarction: a contextual perspective on wives’ distress. J Pers Soc Psychol 61:404–412CrossRefPubMed Coyne JC, Smith DA (1991) Couples coping with a myocardial infarction: a contextual perspective on wives’ distress. J Pers Soc Psychol 61:404–412CrossRefPubMed
27.
go back to reference Langer SL, Brown JD, Syrjala KL (2009) Intrapersonal and interpersonal consequences of protective buffering among cancer patients and caregivers. Cancer 115:4311–4325CrossRefPubMed Langer SL, Brown JD, Syrjala KL (2009) Intrapersonal and interpersonal consequences of protective buffering among cancer patients and caregivers. Cancer 115:4311–4325CrossRefPubMed
28.
go back to reference Lee ML, Schellekens MPJ (2020) Bridging the distance: continuing psycho-oncological care via video-consults during the COVID -19 pandemic. Psychooncology 29:1421–1423CrossRefPubMedPubMedCentral Lee ML, Schellekens MPJ (2020) Bridging the distance: continuing psycho-oncological care via video-consults during the COVID -19 pandemic. Psychooncology 29:1421–1423CrossRefPubMedPubMedCentral
29.
go back to reference Calderon C, Gomez D, Carmona-Bayonas A, Hernandez R, Ghanem I, Gil Raga M et al (2021) Social support, coping strategies and sociodemographic factors in women with breast cancer. Clin Transl Oncol 23:1955–1960CrossRefPubMed Calderon C, Gomez D, Carmona-Bayonas A, Hernandez R, Ghanem I, Gil Raga M et al (2021) Social support, coping strategies and sociodemographic factors in women with breast cancer. Clin Transl Oncol 23:1955–1960CrossRefPubMed
30.
go back to reference Bottaro R, Faraci P (2022) The influence of socio-demographics and clinical characteristics on coping strategies in cancer patients: a systematic review. Support Care Cancer 30:8785–8803CrossRefPubMed Bottaro R, Faraci P (2022) The influence of socio-demographics and clinical characteristics on coping strategies in cancer patients: a systematic review. Support Care Cancer 30:8785–8803CrossRefPubMed
31.
go back to reference Hayes SC, Pistorello J, Levin ME (2012) Acceptance and commitment therapy as a unified model of behavior change. Couns Psychol 40:976–1002CrossRef Hayes SC, Pistorello J, Levin ME (2012) Acceptance and commitment therapy as a unified model of behavior change. Couns Psychol 40:976–1002CrossRef
32.
go back to reference González-Fernández S, Fernández-Rodríguez C (2019) Acceptance and commitment therapy in cancer: review of applications and findings. Behav Med 45:255–269CrossRefPubMed González-Fernández S, Fernández-Rodríguez C (2019) Acceptance and commitment therapy in cancer: review of applications and findings. Behav Med 45:255–269CrossRefPubMed
33.
go back to reference Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA et al (2010) Early palliative care for patients with metastatic non–small-cell lung cancer. N Engl J Med 363:733–742CrossRefPubMed Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA et al (2010) Early palliative care for patients with metastatic non–small-cell lung cancer. N Engl J Med 363:733–742CrossRefPubMed
Metadata
Title
What patients with advanced cancer experience as helpful in navigating their life with a long-term response: a qualitative study
Authors
Laura C. Zwanenburg
Marije L. van der Lee
José J. Koldenhof
Karijn P. M. Suijkerbuijk
Melanie P. J. Schellekens
Publication date
01-04-2024
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 4/2024
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-024-08398-2

Other articles of this Issue 4/2024

Supportive Care in Cancer 4/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine